Stella’s US menopause service combines clinical visits with an app and wellness coaching. It explicitly says clinicians can prescribe nonhormonal treatments, and it also describes care that can focus on non-medication approaches. Those are meaningful service features, but their proximity on a page should not turn them into one intervention with a single evidence claim.
This September 29, 2026 review concerns the US service, not Stella’s UK information. It examines the public care description, prices and the difference between a prescribing decision and everyday support. No consultation, app experience or patient outcome was tested. The exact nonhormonal medicine and the arrangements appropriate to an individual remain unconfirmed.
The US clinic describes choices without naming every prescription
The US homepage says clinicians may prescribe hormonal or nonhormonal treatments according to history, symptoms and preferences. It mentions nonhormonal options for sleep, mood and hot flashes without naming the exact preparation that a future patient would receive. The visit-goals guide is useful before those categories become a medicine discussion. A symptom label such as poor sleep can describe an experience without identifying its cause or a suitable treatment. Ask what the clinician thinks the proposed option would address and which information is still needed. The menu does not establish that one medicine treats every listed concern.
Coaching access is not an additional prescribing professional
Stella’s care description says the app becomes available after a first visit and offers wellness coaching, resources and habit support. Those features are distinct from the clinician who assesses treatment and sends prescriptions. The review does not treat unlimited coaching as unlimited medical review, emergency coverage or confirmation that a prescription can be changed through a coach. Clarify where medication questions and new concerns should go, and which professional is responsible for answering them. This is an organizational question, not criticism of support services. Clear roles make it easier to understand what an advertised care package actually provides.
The evidence question needs the particular technique and outcome
The 2023 nonhormone position-statement abstract supports cognitive behavioral therapy for vasomotor symptoms while distinguishing it from other approaches. That finding cannot authenticate every coaching conversation, mindfulness exercise or audio resource in an app. The relevant questions are which technique is offered, who delivers it and what outcome is being addressed. Stella’s homepage describes a broad support offering rather than a trial of the entire app for every symptom. A reader can find educational or practical support useful without converting that usefulness into proof of a specific hot-flash treatment effect. This assessment does not measure either experience.
New medicine information should not be inferred from the general menu
FDA’s Lynkuet snapshot records approval of elinzanetant in October 2025. Its current label, revised August 2026, contains its own warnings and clinical evaluation requirements. These records demonstrate why a dated general description of nonhormonal care is not a complete current formulary or safety guide. They do not show that Stella prescribes Lynkuet. The elinzanetant evidence guide considers the medicine separately. If it or another treatment is raised in a consultation, ask for information corresponding to that actual product rather than treating a broad FDA-regulated phrase as a complete approval and safety determination.
Use the self-pay prices without turning the average copay into a quote
The US FAQ on the homepage lists an initial self-pay visit at $200 and follow-up visits at $90 each. It also describes an average insurance copay of $45 while warning that coverage varies. An average is not a prospective patient’s verified amount. Medicines are paid through the pharmacy, with cost depending on the preparation, plan and dispensing arrangement. Our Pandia assessment concerns a different recurring clinical-payment structure. Comparing those models requires the number and type of services actually proposed; multiplying a headline figure cannot establish a complete cost of treatment that has not yet been selected. The page’s use of unlimited for wellness coaching should not be read as eliminating the stated follow-up visit fee. It describes a different component of the service. Before joining, establish whether another clinical appointment will be needed for the proposed care and how it would be billed, without assuming a universal visit schedule.
Age, location and referral needs stay part of access
Stella describes its US service as designed for women aged thirty-five to seventy and advertises clinicians across fifty states. Those published boundaries are not an individual eligibility confirmation. Its care description includes coordination and referrals, which also means a telehealth relationship may involve services outside the platform. Our Wisp review examines another online menopause service with a differently specific hormone-free product offer. The relevant comparison is what each source establishes, not the assumption that online care makes every appointment or medicine available everywhere. Confirm the applicable professional, location and financial terms before interpreting a booking link as acceptance.
The plan should make the connection between treatment and support visible
A clear Stella proposal would distinguish the clinical decision from the app and coaching resources, then explain how both relate to the person’s stated goal. A general resource may support understanding without replacing a medicine’s warnings or a clinician’s judgment. The medicine-family guide offers background for that discussion without directing a choice. This review confirms a US clinical service that explicitly includes nonhormonal options. It does not confirm a named prescription, a complete cancellation agreement, app effectiveness or an individual’s likely benefit. Those limits should remain visible even when the service presentation makes the experience look simple.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Stella US: Menopause careUS clinical offer, age/access and payment information; nonhormonal category and coaching do not identify a particular medicine · Checked 2026-09-29
- The Menopause Society: 2023 nonhormone therapy position statementPubMed primary professional abstract; vasomotor-symptom evidence categories, dated 2023 and not provider-specific efficacy or later-drug approval · Checked 2026-09-29
- FDA: Drug Trials Snapshot, LynkuetOriginal FDA approval and trial-population summary; not a complete current label or provider offering · Checked 2026-09-29
- DailyMed: Lynkuet elinzanetant capsulesExact current label revised August 2026; product-specific warnings and use, not a claim any reviewed clinic supplies it · Checked 2026-09-29